Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Puma BiotechnologyPBYI +4.76%53 Gross-Profit-to-Asset % is 91.38% as of Jun. 2026. GuruFocus rates PBYI with a GF Score™ of 53/100 and a GF Value™ of $3.60 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 959 Biotechnology companies, Puma Biotechnology ranks better than 95.72% on this metric.
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Puma Biotechnology's annualizedGross Profit for the quarter that ended in Jun. 2026 was $176.1 Mil.
Puma Biotechnology's average Total Assets over the quarter that ended in Jun. 2026 was $192.7 Mil. Therefore, Puma Biotechnology's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2026 was 91.38%.
Puma Biotechnology Gross-Profit-to-Asset % Related Terms
Puma Biotechnology Gross-Profit-to-Asset % Historical Data
* Premium members only.
The historical data trend for Puma Biotechnology's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBYI vs EVMN, OCGN, EDIT: Gross-Profit-to-Asset % Comparison
For the Biotechnology subindustry, Puma Biotechnology's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Puma Biotechnology Gross-Profit-to-Asset % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Jun. 2026) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
What does a Gross-Profit-to-Asset % of 91.38% mean?
Puma Biotechnology (PBYI) has a Gross-Profit-to-Asset % of 91.38% as of Jun. 2026. Gross Profit to Asset Ratio is the total gross profit divided by total assets. View historical data on Puma Biotechnology and its competitors. According to the industry distribution chart, Puma Biotechnology ranks #41 out of 959 companies in the Biotechnology industry, placing it in the top 4.3%.
Is Puma Biotechnology's Gross-Profit-to-Asset % too high?
Puma Biotechnology's current Gross-Profit-to-Asset % is 91.38%. The Biotechnology industry median Gross-Profit-to-Asset % is 11.84. Puma Biotechnology's value of 91.38% is 671.8% above this industry median. Based on the distribution chart, Puma Biotechnology ranks #41 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's Gross-Profit-to-Asset % compare to EVMN and OCGN?
According to the Biotechnology industry distribution chart, Puma Biotechnology ranks #41 out of 959 companies for Gross-Profit-to-Asset %. This places Puma Biotechnology in the top 4% of its industry — outperforming the majority of peers. The industry median Gross-Profit-to-Asset % is 11.84. Puma Biotechnology's value of 91.38% is 671.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross-Profit-to-Asset % for a Biotechnology company?
The median Gross-Profit-to-Asset % among Biotechnology companies is 11.84, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Gross-Profit-to-Asset % significantly above this median, while those in the bottom quartile fall well below. However, Gross-Profit-to-Asset % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Puma Biotechnology's current Gross-Profit-to-Asset % of 91.38% is 671.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross-Profit-to-Asset % mean?
A high Gross-Profit-to-Asset % can signal that a stock is expensive relative to its fundamentals. Gross Profit to Asset Ratio is the total gross profit divided by total assets. View historical data on Puma Biotechnology and its competitors. For the Biotechnology industry, the median Gross-Profit-to-Asset % is 11.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Puma Biotechnology's current Gross-Profit-to-Asset % is 91.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.60, compared to a current price of $9.25 — trading 156.9% above its estimated fair value. The current Gross-Profit-to-Asset % is 91.38% and 671.8% above the Biotechnology industry median of 11.84. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross-Profit-to-Asset % calculated?
Gross-Profit-to-Asset % is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current Gross-Profit-to-Asset % is 91.38% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Puma Biotechnology (PBYI) Overvalued in 2026?
Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued.
The current stock price of $9.25 is trading 156.9% above its estimated GF Value™ of $3.60.
GuruFocus considers Puma Biotechnology to be Significantly Overvalued.
Key valuation signals for PBYI:
Gross-Profit-to-Asset %: 91.38%
GF Value™: $3.60 vs. price of $9.25 (156.9% above fair value)
Industry Position: 671.8% above the Biotechnology median (#41 of 959)
No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score
Get the complete analysis for PBYI
Gross-Profit-to-Asset % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBYI has been successfully added to your 
